





coviself kit
Product Details:
coviself kit Price And Quantity
- 1.2-1.5 USD ($)/Box
- 1.20 - 1.50 USD ($)/Box
- 1 Box
coviself kit Trade Information
- USA
- Letter of Credit (L/C) Western Union Letter of Credit at Sight (Sight L/C) Telegraphic Transfer (T/T)
- 3 Box Per Day
- 5-15 Days
- Yes
- Free samples are available
- 2 Nasal Swabs, individually packed 2 Test Reading Cards, individually packed 1 Instructions for Use 2 Sample Preservation Solution Tubes, individually packed 1 Quick Start Guide
- South America Western Europe Eastern Europe Central America Middle East Asia North America Australia Africa
- coviself kit.FDA EUA CE ISO GMP SFC ETC
Product Description
The iHealth COVID-19 Antigen Rapid Test is a lateral flow assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2.
Please refer to the downloads section below for a full test facts sheet,coviself kit FDA-EUA documentation, and the instructions for use documents.
For use with anterior nasal swab specimens
For in vitro Diagnostic Use Only
This product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization (EUA)
Does not differentiate between SARS-CoV and
SARS-CoV-2.
Results are for the identification of the SARS-CoV-2 nucleocapsid protein antigen.
This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.coviself kit This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.
This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.